Search
BioNTech's U.S. Stock Premarket Jumps Nearly 12% on Multi-Billion Dollar Licensing Deal
1 week ago /
Read about 0 minute
Author：小编
Shares of BioNTech in the U.S. premarket surged nearly 12%, building on a previous trading day's close that was up over 18%. This significant upswing can be attributed to the company's licensing agreement with Bristol-Myers Squibb for the novel anti-cancer drug BNT327, which includes milestone payments that could potentially total up to $11.1 billion.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
